» Articles » PMID: 7962603

Comparison of New Immunohistochemical Assay for Oestrogen Receptor in Paraffin Wax Embedded Breast Carcinoma Tissue with Quantitative Enzyme Immunoassay

Overview
Journal J Clin Pathol
Specialty Pathology
Date 1994 Oct 1
PMID 7962603
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To validate the use of a new mouse monoclonal antibody (1D5) directed against the N-terminal domain (A/B region) of the oestrogen receptor in an immunohistochemical assay (ER-IHA) for paraffin wax embedded tissue.

Methods: Breast cancer specimens were surgically obtained from 119 previously untreated patients. For comparison, oestrogen receptor was measured from cytosol fractions using an established oestrogen receptor enzyme immunoassay (ER-EIA) method. Oestrogen receptor "H-scores" were obtained from the ER-IHA after antigen retrieval using microwave treatment. Where discrepancies occurred between the two methods, further immunohistochemistry was performed using the H222 antibody from the Abbott Laboratories ER-ICA kit.

Results: The correlation between the two methods was non- linear, but despite this there was an 86% concordance between ER-EIA and ER-IHA using the 1D5 ER antibody. Fifty four per cent of tumours (64/119) were oestrogen receptor positive and 32% (38/119) were negative by both assays. A mismatch between the ER-EIA and ER-IHA occurred in 17 cases. Seven tumours were IHA positive but EIA+, but five of these were borderline negative by EIA, having values of > 5 and < 10 fmol/mg protein. Ten tumours were IHA negative and EIA+; four of these tumours were completely negative by IHA in the section studied. A further IHA assay, carried out on the 17 tumour mismatches with H222 antibody, showed that three tumours remained substantially discordant. These three tumours were strongly positive with the 1D5 antibody and negative with the H222 antibody. Two of these discordant tumours were of the rare ER negative and PgR positive phenotype and may contain oestrogen receptor that is of biological interest but which lacks the hormone binding epitope.

Conclusions: The concordance between the classic enzyme immunoassay technique and the new immunohistochemical method on paraffin wax embedded sections was good. Moreover, the IHA technique using the 1D5 antibody against the N-terminal was easily reproducible. This technique may allow oestrogen receptor content to be determined in large cohorts of patients in whom archival tumour material is available.

Citing Articles

Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy.

Dou H, Li F, Wang Y, Chen X, Yu P, Jia S Diagn Pathol. 2024; 19(1):5.

PMID: 38178166 PMC: 10765627. DOI: 10.1186/s13000-023-01433-6.


Is oestrogen receptor-negative/progesterone receptor-positive (ER-/PR+) a real pathological entity?.

Onitilo A, Engel J, Joseph A, Li Y Ecancermedicalscience. 2021; 15:1278.

PMID: 34567263 PMC: 8426004. DOI: 10.3332/ecancer.2021.1278.


Integrative Analyses of Uterine Transcriptome and MicroRNAome Reveal Compromised LIF-STAT3 Signaling and Progesterone Response in the Endometrium of Patients with Recurrent/Repeated Implantation Failure (RIF).

Choi Y, Kim H, Lim E, Park M, Yoon J, Kim Y PLoS One. 2016; 11(6):e0157696.

PMID: 27304912 PMC: 4909214. DOI: 10.1371/journal.pone.0157696.


Lymphatic-targeted therapy following neoadjuvant chemotherapy: a promising strategy for lymph node-positive breast cancer treatment.

Chen J, Yao Q, Wang H, Wang B, Zhang J, Wang T Med Oncol. 2015; 32(7):184.

PMID: 26008153 DOI: 10.1007/s12032-015-0634-7.


Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study.

Chen J, Yao Q, Li D, Zhang J, Wang T, Yu M BMC Cancer. 2013; 13:248.

PMID: 23693018 PMC: 3664086. DOI: 10.1186/1471-2407-13-248.


References
1.
Andersen J, Thorpe S, KING W, Rose C, Christensen I, Rasmussen B . The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays. Eur J Cancer. 1990; 26(4):442-9. DOI: 10.1016/0277-5379(90)90013-j. View

2.
Al Saati T, Clamens S, Faye J, Prats H, Coindre J, Wafflart J . Production of monoclonal antibodies to human estrogen-receptor protein (ER) using recombinant ER (RER). Int J Cancer. 1993; 55(4):651-4. DOI: 10.1002/ijc.2910550423. View

3.
Hsu S, RAINE L, FANGER H . Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29(4):577-80. DOI: 10.1177/29.4.6166661. View

4.
Greene G, JENSEN E . Monoclonal antibodies as probes for estrogen receptor detection and characterization. J Steroid Biochem. 1982; 16(3):353-9. DOI: 10.1016/0022-4731(82)90045-0. View

5.
Harland R, Barnes D, Howell A, Ribeiro G, Taylor J, SELLWOOD R . Variation of receptor status in cancer of the breast. Br J Cancer. 1983; 47(4):511-5. PMC: 2011332. DOI: 10.1038/bjc.1983.81. View